Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Achillion Pharmaceuticals, Inc.    ACHN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Achillion Shares Slide On Results From Hepatitis C Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 04:57pm CET

Achillion Pharmaceuticals Inc.'s (>> Achillion Pharmaceuticals, Inc.) shares declined Monday as Phase II study data for its lead hepatitis C treatment was deemed disappointing in light of the recent success of peers.

Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.), Gilead Sciences Inc. (>> Gilead Sciences, Inc.) and others, including Abbott Laboratories (>> Abbott Laboratories), are racing to bring an all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. Gilead shares surged last week as it appeared to be leading the race: it hopes to bring a GS-7977-based therapy to market late next year or in 2014.

Achillion shares were down 12% at $7.25 in recent trading, pushing their decline for the past three months to 21%.

Over the weekend, Achillion presented final results of a 12-week study of its ACH-1625 treatment in combination with standard-of-care treatment at a European Association for the Study of the Liver conference in Barcelona, along with plans to combine a study of the oral drug candidate with another treatment later this year.

The company on Saturday had reported that in the second segment of its Phase 2a trial of ACH-1625, 94% to 100% of patients achieved a complete early virologic response after 12 weeks of the experimental treatment in combination with pegylated interferon alfa-2a and ribavirin. The company also reported the combined treatments were safe and well tolerated and produced high viral response rates.

J.P. Morgan Chase & Co. (JPM) said in a research note the data Achillion presented on Saturday "raises eyebrows" as it downgraded the stock to market perform from market outperform.

"Overall, the data were confusing and raised questions regarding the interim safety and efficacy analysis, particularly regarding the compounds ability to clear the virus relative to other competitive agents, liver elevations, and gastrointestinal symptoms," the analysts said. "As such, we are waiting on the sidelines until we get a better handle on the breadth of the therapeutic window."

Achillion on Monday aimed to clarify data regarding end-of-treatment data included in the data presented over the weekend.

The company in a statement said that 58 patients were given a once-daily dose of 200 milligrams, 400 milligrams or 800 milligrams of ACH-1625 pegylated interferon and ribavirin for 12 weeks. At the time of the presentation, 22 of the patients had completed 12 weeks of ACH-1625 plus the other two drugs followed by 12 weeks of pegylated interferon and ribavirin. At the end of 24 weeks all 22 patients had undetectable levels of the virus.

"We are providing these results as we recognized that some of the data was not clear" during its presentation at the conference, Achillion President and Chief Executive Michael Kishbauch said.

Oppenheimer analysts said earlier Monday that based on the results, "we believe '1625 has meaningful strategic value and could play a role in an all-oral combination regimen."

However, the analysts also said that despite their favorable view of 1625 and Achillion's earlier hepatitis C pipeline they believe the stock currently "reflects appropriate value for these programs."

The study data was released a few days after another study found a regimen combining experimental drugs from Gilead and Bristol-Myers suppressed the hepatitis C virus in most patients four weeks after completing treatment. In a separate study, Gilead also said a combination of its drug, GS-7977, with an older drug, ribavirin, suppressed the liver-disease-causing virus in most patients four weeks after treatment.

The results bolster the prospects for an all-oral regimen for hepatitis C that eliminates an injectable drug used in the current standard treatment, interferon, which can be difficult for patients to tolerate.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACHILLION PHARMACEUTICALS,
01/11 WEDNESDAY SECTOR LAGGARDS : Drugs, Biotechnology Stocks
2016 ACHILLION PHARMACEUTICALS : Announces Clinical Milestone for the Advancement of ..
2016 ACHILLION PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Fina..
2016 ACHILLION PHARMACEUTICALS : Announces Clinical Milestone for the Advancement of ..
2016 Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Pha..
2016 INSIDER TRADING ACTIVITY ACHILLION P : ACHN) – Director Bought 10,000 shar..
2016 WEBSTER FINANCIAL : Bank's John Ciulla Elected CBIA Board Chair
2016 Data Presented at American Society of Hematology Meeting Demonstrate Potentia..
2016 ACHILLION PHARMACEUTICALS : Announces Initiation of Patient Dosing by Janssen in..
2016 Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Shor..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
2016 Achillion Pharmaceuticals - Taking Its First Steps After HCV
2016 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Fold, gte
2016 After Hours Gainers / Losers
2016 Ash Abstract Dump Poorly Timed For Biotech Investors
Advertisement
Financials ($)
Sales 2016 -
EBIT 2016 -86,3 M
Net income 2016 -83,9 M
Debt 2016 376 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 0
EV / Sales 2017 16,2x
Capitalization 574 M
More Financials
Chart ACHILLION PHARMACEUTICALS,
Duration : Period :
Achillion Pharmaceuticals, Technical Analysis Chart | ACHN | US00448Q2012 | 4-Traders
Full-screen chart
Technical analysis trends ACHILLION PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 8,17 $
Spread / Average Target 94%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Milind S. Deshpande President, Chief Executive Officer & Director
David I. Scheer Chairman
Mary Kay Fenton CFO, Executive VP & Investor Relations Contact
David Apelian Chief Medical Officer & Executive Vice President
Joel C. Barrish Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACHILLION PHARMACEUTIC..1.69%574
AMGEN, INC.6.78%116 141
GILEAD SCIENCES, INC.2.04%96 267
CELGENE CORPORATION1.49%91 071
REGENERON PHARMACEUTIC..0.29%38 830
ACTELION LTD4.90%24 706
More Results